Friday, December 30, 2011

Bought More NeuroMetrix (NURO)

I felt like buying some stock on the last trading day of the year, so I bought a tiny bit of NeuroMetrix (NURO) at $1.29 per share. 52-week range: $1.15 - $4.20. PSR (Price-Sales-Ratio): 0.45

NeuroMetrix executed a 1:6 stock split on 02011.09.02. There 3.89M NURO shares outstanding with ~22% of them closely held (i.e. NURO has a thin float of ~2.2M).

Balance sheet data: $3.01 in cash; minimal debt (debt/equity ratio of 0.33); current ratio 5:22.

A couple of days ago, NeuroMetrix issued a press release titled "Commercial Milestone 100th NC-stat® DPNCheck™ Order". The following was copied from the press release.

“We are pleased with initial market reaction to NC-stat DPNCheck” said Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer. “Approximately 200 physicians, mostly endocrinologists and podiatrists, in 100 medical practices are now using the device to improve their management of DPN. This achievement comes three months after commercial launch."

I would have liked to bought more, but cash was a limiting factor.

No comments:

Post a Comment